Innovations In Clinical Neuroscience

NOV-DEC 2017

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link:

Contents of this Issue


Page 57 of 83

58 ICNS INNOVATIONS IN CLINICAL NEUROSCIENCE November-December 2017 • Volume 14 • Number 11–12 R E V I E W CONCLUSION Looking forward, the availability of transformed PANSS factors should provide a more valid method for measuring domain- specific effects of candidate antipsychotics, especially candidate drugs with non-D 2 receptor binding mechanisms of action. It is hoped that the availability of valid measures of symptom change, without the confound of pseudospecificity, might facilitate the drug development process, permitting a more accurate characterization of the efficacy of putative new agents in targeting specific symptom domains in patients with psychotic illness. REFERENCES 1. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13: 261–276. 2. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:790–812. 3. Singh MM, Kay SR. A comprehensive study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia: theoretical implications for potency differences among neuroleptics. Psychopharmacologia. 1975;43:115–123. 4. Crow T. Molecular pathology of schizophrenia: more than one dimension of pathology? BMJ. 1980;280:66–68. 5. Kay SR, Opler LA, Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) Manual. Toronto, ON: Multi-Health Systems Inc.; 2000. 6. Lindenmayer JP, Bernstein-Hyman R, Grochowski S, et al. Psychopathology of schizophrenia: initial validation of a five-factor model. Psychopathology. 1995;28:22–3. 7. Lindenmayer JP, Grochowski S, Hyman RB. Five factor model of schizophrenia: replication across samples. Schizophr Res. 1995;14:229–234. 8. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58:538–546. 9. Emsley R, Rabinowitz J, Torreman M, Group R-I-EPGW. The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophr Res. 2003;61:47–57. 10. Wallwork RS, Fortgang R, Hashimoto R, et al. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res. 2012;137:246–250. 11. Hopkins SC, Ogirala A, Loebel A, Koblan KS. Transformed PANSS factors intended to reduce pseudospecificity among symptom domains and enhance understanding of symptom change in antipsychotic-treated patients with schizophrenia. Schizophr Bull 2017 Sep 11. doi: 10.1093/schbul/sbx101. [Epub ahead of print]. 12. Galderisi S, Merlotti E, Mucci A. Neurobiological background of negative symptoms. Eur Arch Psychiatry Clin Neurosci. 2015;265:543–58 13. Gruber O, Santuccione AC, Aach H. Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system. Front Psychiatry. 2014;5:32. 14. Zhu J, Zhuo C, Liu F, et al. Neural substrates underlying delusions in schizophrenia. Sci Rep. 2016;6:33857. 15. Leber P. Regulatory issues, p.485-494. In: Kenneth L. Davis DC, Joseph T. Coyle, and, Nemeroff C, eds. Neuropsychopharmacology: The Fifth Generation of Progress: Lippincott, Williams, & Wilkins, Philadelphia, PA, 2002. 16. Laughren T, Levin T. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr Bull. 2006;32:220-222. 17. Raskin A, Pelchat R, Sood R, et al. Negative symptom assessment of chronic schizophrenia patients. Schizophr Bull. 1993;19:627-35. 18. Axelrod BN, Goldman RS, Woodard JL, Alphs LD. Factor structure of the negative symptom assessment. Psychiatry Res. 1994;52:173–9. 19. Garcia-Portilla MP, Garcia-Alvarez L, Saiz PA, et al. Psychometric evaluation of the negative syndrome of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2015;265:559–566. 20. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203–213. 21. Keefe RS, Haig GM, Marder SR, et al. Report on ISCTM consensus meeting on clinical assessment of response to treatment of cognitive impairment in schizophrenia. Schizophr Bull. 2016;42:19–33. 22. Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145:101–9. ICNS

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - NOV-DEC 2017